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Abstract Cytochrome b5 reductase 2 (CYB5R2), a member
of the flavoprotein pyridine nucleotide cytochrome reductase
family, is associated with a number of physiological reactions.
However, its role in cancer, especially nasopharyngeal carci-
noma (NPC), has not been addressed. Here, we investigate the
transcript levels and promoter methylation status of CYB5R2
in NPC derived cell lines and tumor biopsies and experimen-
tally address its role as a tumor suppressor gene. We find that
CYB5R2 transcript levels are decreased in NPC cell lines and
tumor biopsies. Promoter hypermethylation of CYB5R2 was
detected in all six tested NPC cell lines and in 84% of primary
NPC tumor biopsies but not in normal nasopharyngeal epi-
thelium. Clinically, CYB5R2 methylation was associated with
lymph node metastasis in NPC patients (P <0.05). The endog-
enous expression of CYB5R2 could be restored in vitro by the
methyltransferase inhibitor 5-aza-2′-deoxycytidine in NPC
cell lines. Ectopic expression of CYB5R2 had an inhibitory
effect on proliferation, clonogenicity and migration of NPC
cells. Moreover, in vivo tests in nude mice indicated that
ectopic expression of CYB5R2 reduces the tumorigenicity of
CYB5R2-negative NPC cells. Collectively, these findings sug-
gest thatCYB5R2 may be a functional tumor suppressor gene,
frequently inactivated by hypermethylation of its promoter in
NPC. We report here the first instance of epigenetic downreg-
ulation in NPC tumor biopsies of a key enzyme, CYB5R2,
which is responsible for the detoxification of environmental
carcinogens. We propose the possibility of utilizing CYB5R2
promoter methylation as a diagnostic biomarker of NPC in the
future.
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Introduction
Nasopharyngeal cancer (NPC) is one of the most common
head and neck malignant tumors in Southern China, with an
annual incidence rate of 25–50 per 100,000 person-years,
while the frequency in Caucasians in other countries is less
than one case per 100,000 person-years [1, 2]. The etiology of
NPC is multifactorial. Accumulated epidemiological and eti-
ological evidence indicate that NPC develops as a result of a
complex interaction between genetic factors, exposure to
chemical carcinogens, and latent Epstein–Barr virus (EBV)
infection [3–6]. Specially, environmental factors such as con-
sumption of salt-preserved fish, cigarette smoking and expo-
sure to environmental chemical pollutants have been reported
to be of importance in the development of NPC [3, 7, 8]. EBV
is strongly associated with NPC, and it has now been found to
function as a tumor promoter rather than an initiator in the
tumorigenesis of NPC. But the fact that the majority of the
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human population (>90 %) carry EBV suggest that host
genetic factors might also contribute to the carcinogenesis of
NPC, making it develop only in a small subset of the exposed
population. However, the relative contribution of these factors
in the pathogenesis of NPC remains to be elucidated in detail.
Recent studies demonstrate that genes for carcinogen-
metabolizing enzymes may play critical roles in determining
individual susceptibility to NPC. Genetic or epigenetic alter-
ations that alter the expression or function of these genes, may
decrease the efficiency of the corresponding carcinogen de-
toxification processes, which, in turn, may increase individual
susceptibility and cancer risk. Xenobiotics can be detoxified
by phase I or II biotransformation enzymes [9], and genetic
polymorphisms in genes encoding biotransformation enzymes
such asCYP2E1 ,GSTM1 andGSTT1 were shown to increase
individual susceptibility to NPC [10–13].
Furthermore, growing evidence demonstrates that aberrant
epigenetic changes, especially promoter hypermethylation of
tumor suppressor genes (TSGs), are important in the multistep
carcinogenesis of NPC [14, 15]. However, no studies have
looked into the association of epigenetic alterations in
xenobiotic-metabolizing enzymes and NPC.
The human CYB5R2 (cytochrome b5 reductase 2), a 276-
amino-acid protein, contains one ferredoxin reductase-type
flavin adenine dinucleotide-binding domain and belongs to
the flavoprotein pyridine nucleotide cytochrome reductase
family. It is one of the phase I xenobiotic biotransformation
enzymes responsible for detoxification of polycyclic aromatic
hydrocarbons and arylhydroxylamine carcinogens, common-
ly found in cigarette smoke and fried foods [16]. CYB5R2 is
involved in various biological processes such as electron
transport, oxidation–reduction, lipid metabolism, fatty acid
desaturation and/or elongation, cholesterol biosynthesis, drug
metabolism, and methemoglobin reduction in erythrocytes
[17]. Moreover, it is responsible for reducing both NADH-
dependent lucigenin chemiluminescence and 2-[4-
iodophenyl]-3-[4-nitrophenyl]-5-[2, 4-disulfophenyl]-2H -tet-
razolium monosodium salt in human spermatozoa [17].
In this study, we evaluated the transcriptional levels and
methylation status of CYB5R2 in NPC cell lines and primary
tumor biopsies. We further addressed the TSG properties of
CYB5R2 in NPC by a series of in vitro and in vivo
experiments.
Materials and methods
NPC cell lines, primary tumor biopsies and normal
nasopharyngeal epithelium (NNE)
Six NPC cell lines (CNE1, CNE2, TW03, C666-1, HNE1,
and HONE1) were maintained at 37 °C in the appropriate
medium. In total, 70 NPC primary tumor biopsies were
collected from newly diagnosed and untreated NPC patients
at the department of Otolaryngology—Head and Neck Sur-
gery, First Affiliated Hospital of Guangxi Medical University
(Nanning, China), with informed consent from the donors.
The diagnosis was established by experienced pathologists
according to the World Health Organization (WHO) classifi-
cation for NPC. Twenty-four NNE tissues obtained by tonsil-
lectomy were included as controls. In all, 50 of the 70 NPC
biopsies and 12 of the 24 NNEs were processed for DNA
extraction, the rest 20 NPC and 12 NNEs were used for RNA
extraction. All biopsy samples were stored in liquid nitrogen.
Ethical permission for this study was granted by the Ethical
Review Committee of First Affiliated Hospital of Guangxi
Medical University, China.
Semi-quantitative RT-PCR
Preparation of total RNA, first-strand synthesis of cDNA and
RT-PCR was performed as described [18]. All primer se-
quences, annealing temperatures, cycling conditions and ex-
pected PCR product sizes are listed in Table 1.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) was
amplified from the same cDNA sample as an internal control.
The amplified PCR products were visualized after electropho-
resis in 2 % agarose gels and semi-quantitative analysis was
performed using Quantity One v4.4.0 software (Bio-Rad,
USA).
Methylation-specific PCR (MSP) and bisulfite genomic
sequencing (BGS)
The procedure for sodium bisulfite modification of DNAwas
performed as described [18, 19]. Bisulfite-modified DNAwas
amplified using MSP, with primer sets specifically detecting
methylated or unmethylated alleles. PCR products were sep-
arated on agarose gels. MSP analyses were performed in
duplicate. To analyze the methylation status of the targeted
region in the CYB5R2 promoter, bisulfite-treated DNA was
amplified with a BGS PCR primer set. Amplified PCR prod-
ucts were subcloned and transformed into JM109 competent
cells. Several isolated plasmid clones from each cell line or
biopsy were sequenced using the BigDye terminator-cycle
sequencing kit 3.0 (Applied Biosystems, USA) on an ABI
3100 sequencer.
5-Aza-2′-deoxycytidine (5-aza-dC) treatment
Four NPC cell lines (CNE1, CNE2, HONE1 and C666-1)
were seeded into six-well plates at 2×105 cells/well. The next
day, cells were treated with the DNA methyltransferase inhib-
itor 5-aza-dC (Sigma) at 10 μM for 96 h, and medium with
freshly added 5-aza-dC was replaced every 24 h. Total RNA
was extracted for semi-quantitative RT-PCR as described.
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Vector construction and transfection
The full-length coding sequence of CYB5R2 from Origene
(USA) was subcloned into the pCMV-Tag3Avector (Stratagene,
USA). The NPC cell line HONE1, which showed downregulat-
ed CYB5R2, was transfected with the pCMV-Tag3A-CYB5R2
plasmid or control pCMV-Tag3A using Lipofectamine 2000
(Invitrogen, USA). Stable clones were obtained by G418 selec-
tion (400 μg/ml) for 2 weeks and maintained in 200 μg/ml G418.
Colony formation assay
Aliquots of 1×105 HONE1 cells were transfected as described
above. After 48 h, the cells were transferred to 60-mm cell
culture dishes and selected in 400 μg/ml G418 for 2 weeks.
Giemsa-stained colonies were photographed and counted
using the Quantity One v4.4.0 software (Bio-Rad, USA).
The experiment was performed in triplicate.
Cell proliferation assay
To determine the cell proliferation rate, stably transfected
empty vector-HONE1 and CYB5R2 -HONE1 cells were seed-
ed into 96-well plates at 2×103 cells per well. Cell density at
different time points was measured using the vital stain 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Solarbio) and the absorbance (OD490 nm) was mea-
sured in a microplate reader (iMark, Bio-Rad, USA). Cells
were cultured for 5 days, and five wells from each group were
chosen as replicates every 24 h.
Wound healing assay
Empty vector-HONE1 and CYB5R2 -HONE1 cells (5×105 per
well) were seeded in six-well plates and allowed to adhere for
24 h. Confluent monolayers of cells were scratched by a sterile
1 ml micropipette tip. Photographs were taken at 0 and 24 h at
the same position of the wound and the regrowth of cells into
the wound area was measured. The experiment was performed
in triplicate.
In vivo tumor growth assay
Eight female 6-week-old Balb/c athymic nude mice (Experi-
mental Animal Center of Guangxi Medical University, China)
were used. The experimental protocol for tumor formation in
nude mice was approved by the Ethical Review Committee of
First Affiliated Hospital of Guangxi Medical University, and
the committee's ethical guidelines for animal experimentation
were followed. A total of 2×106 HONE1 cells, stably
transfected with CYB5R2 , were subcutaneously injected into
the right flank of the nude mice. An equal amount of empty
vector-HONE1 cells were injected into the left flank of the
mice as a control. The growth of tumors was monitored every
2 days for 2 weeks after inoculation. Tumor volume (V) was
calculated as V = (π /6)L ×W ×H , where L , W, and H repre-
sent tumor diameters in three mutually orthogonal planes. The
tumor was removed and weighed on day 14.
Statistical analysis
Statistical analysis was performed using SPSS v16 (SPSS
Inc., Chicago, IL, USA). Data are shown as mean±SD. The
association of promoter methylation status with clinical path-
ological features of NPC patients was analyzed by Pearson
chi-square or Fisher's exact test. Paired t test was used to
compare in vivo experiment groups. A P value <0.05 was
considered statistically significant.
Table 1 Primer sequences,
product size and annealing
temperature used in this study





CYB5R2- forward 5′-CCTTGTAGGGACCCGTCCC-3′ 291 66 °C
CYB5R2- reverse 5′-GACAGGGGTGTAAGCCCTG-3′
GAPDH-forward 5′-AAGCTCACTGGCATGGCCTT-3′ 375 60 °C
GAPDH-reverse 5′-CTCTCTTCCTCTTGTGCTCTTG-3′
Methylation-specific PCR
MSP-forward 5′-GGGGAGCGGGTTAGTCGTC-3′ 140 65 °C
MSP-reverse 5′-GAACCCGCAAACTCGTAACGTC-3′
USP-forward 5′-GGGGAGTGGGTTAGTTGTTG-3′ 146 58 °C
USP-reverse 5′-CACCACAAACCCACAAACTC-3′
Bisulfite sequencing PCR
BGS-forward 5′-GGTAGGGTTGATTTAGAGTTAG-3′ 301 58 °C
BGS-Reverse 5′-CTTCAATACTCCATAAATACACC-3′
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Results
Inactivation of CYB5R2 in NPC cell lines and primary tumors
To investigate the expression of CYB5R2 in NPC cell lines
and NPC biopsies, semi-quantitative RT-PCR was performed.
As demonstrated in Fig. 1a, CYB5R2 mRNA expression was
undetectable in NPC cell lines CNE1, HONE1, and HNE1
while weak expression was detected in CNE2, TW03, and
C666-1. As well, CYB5R2 expression was downregulated in
the 20 NPC primary tumor biopsies but easily detected in all
NNE samples (Fig. 1b).
The CYB5R2 promoter is hypermethylated in NPC cell lines
and primary tumors
Having established that CYB5R2 was downregulated in NPC
cell lines and primary biopsies, we further investigated the
promoter methylation status of CYB5R2 . MSP results showed
that the CYB5R2 promoter was hypermethylated in the six
NPC cell lines (CNE1, CNE2, TW03, HONE1, HNE1 and
C666-1; see Fig. 2a) and in 84 % (42/50) of NPC primary
tumors but in none of the 12 NNE samples (Fig. 2b).
Unmethylated amplicons were detected in some primary
NPC biopsy samples but were most likely due to contaminat-
ing non-malignant cells such as stromal cells in a fraction of
the tissue samples.
CpG sites in the CYB5R2 promoter are heavily methylated
in NPC cell lines and NPC biopsies
To reveal the detailed methylation status of individual CpG
sites, we analyzed the DNA sequence of the promoter region
−389 to −89 bp of CYB5R2 using BGS in two NPC cell lines
(TW03 and CNE2), two NPC biopsies (NPC15 and NPC27)
and one normal biopsy (NNE7) (Fig. 2c). All 39 CpG sites
were heavily methylated in TW03 and CNE2, in agreement
with our finding of downregulated CYB5R2 expression in
these NPC cell lines. As well, the two NPC biopsies tested
showed intense methylation. The presence of some
unmethylated CYB5R2 promoter sequences among the clones
originating from the twoNPC cell lines TW03 and CNE2may
be due to heterogeneity in the original cell lines. The NNE
sample was nearly completely free of methylation. The BGS
data also demonstrate that our bisulfite conversion of genomic
DNAwas complete which supports the reliability of our MSP
results.
Transcription of CYB5R2 could be restored by 5-aza-dC
treatment
The expression of CYB5R2 , which was silenced or downreg-
ulated in the NPC cell lines CNE1, CNE2, HONE1 and C666-
1, could be restored after 96 h 5-aza-dC treatment (Fig. 2d).
This provides support for our hypothesis that CYB5R2 down-
regulation in NPC is an epigenetic event and not due to
genetic rearrangement or mutation of the gene or its promoter.
Clinico-pathological significance of CYB5R2 promoter
hypermethylation in NPC
Clinical characters of the 50 NPC patients were collected, and
we found a significant association of CYB5R2 promoter
hypermethylation with the clinico-pathological variable
lymph node metastasis (P <0.05), however, there was no
Fig. 1 Expression of cytochrome
b5 reductase 2 (CYB5R2) in NPC
cell lines, NPC biopsies and NNE
samples. a RT-PCR analysis of
expression of CYB5R2 in NPC
cell lines and NNEs. PC: positive
control. GAPDH was the internal
control. Water was the blank
control. b Semi-quantitative
RT-PCR of CYB5R2 expression
in NNEs and primary NPC
tumors. CYB5R2 expression was
normalized to that of GAPDH
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significant correlation to age, sex, cancer stage, or pathologi-
cal subtypes (Table 2).
Reexpression of CYB5R2 in NPC cells suppresses colony
formation and cell proliferation and inhibits cell migration
To assess whether CYB5R2 might have properties of a TSG in
NPC, we examined the effect of CYB5R2 on clonogenicity
and cell proliferation in HONE1 cells. The number of colonies
was lower for CYB5R2-HONE1 than empty vector-HONE1
cells (P <0.05) (Fig. 3a). As well, CYB5R2 -HONE1 cells
grew significantly slower than HONE1 parental and empty
vector-HONE1 cells (Fig. 3c). To measure the effect of
CYB5R2 reexpression on cell mobility, we used a wound
healing assay. Cell movement into the scratched area was
slower for CYB5R2 -HONE1 than for empty vector-HONE1
cells, which suggests that ectopic expression of CYB5R2
effects a reduction in the motility of NPC cells (Fig. 3b).
Inactivation of CYB5R2 is critical for tumorigenesis in vivo
We further assessed the tumor suppressing capacity of
CYB5R2 in vivo. Empty vector-HONE1 and CYB5R2 -
HONE1 cells were injected into the left and right flanks,
respectively, of Balb/c athymic nude mice and tumor growth
was monitored with 2-day intervals. Mice injected in the
flanks with control cells formed larger tumors within 14 days,
whereas mice injected in the flanks with CYB5R2-HONE1
showed greatly reduced tumor growth (P <0.05) (Fig. 4).
Thus, ectopic expression of CYB5R2 reverses the tumor
growth which is associated with its epigenetic downregulation
in the HONE1 cells.
Discussion
NPC has been proposed to be the result of a multistep process
involving environmental carcinogens, genetic factors and
Fig. 2 Analysis of the methylation status of the CYB5R2 promoter
region in NPC cell lines, NPC primary tumors and NNE samples. a
MSP analysis in NPC cell lines and NNEs. M methylated alleles, U
unmethylated alleles. In vitro methylated DNA was used as a methyla-
tion-positive control and DNA from normal lymphocytes was the positive
control for unmethylated alleles. The blank control was water. b MSP
analysis in NPC biopsies and NNE, representative data is shown. c
Methylation status of the 39 CpG sites of the CYB5R2 promoter in two
NPC cell lines (TW03 and CNE2), two NPC biopsies (NPC15 and 27)
and one NNE biopsy (NNE7). Five clones were randomly selected and
sequenced for each sample. Different size filled sectors of the circles
represent the fraction of methylated CpG. MSP primer locations are
indicated by frames. d Restoration of CYB5R2 expression by treatment
with 5-aza-dC in NPC cell lines. One NNE sample and CYB5R2 expres-
sion plasmid DNAwere used as positive controls
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latent EBV infection. Among these etiologic factors, EBV is a
well-recognized causative factor not only for NPC, but for a
number of humanmalignancies [20]. However, although EBV
infects and persists in about 90 % of the human population,
NPC develops in only a minority of EBV-infected individuals,
which suggests that other risk factors may be involved in
disease development. Environmental factors such as lifestyle
and occupational exposure to chemical carcinogens and tumor
promoters have been suggested as cofactors [3]. Examples of
the most relevant environmental exposures are Cantonese-
style salted fish, fermented fish sauce and other preserved
foods [3, 8]. These foods contain large amounts of N -
nitrosodimethylamine (NDMA), N -nitrosopyrrolidene
(NPYR) and N -nitrosopiperidine (NPIP), which may
Table 2 Association of CYB5R2
promoter methylation status and
clinicopathological characteristics
of NPC patients
Data are number of patients
NS not significant
a According to the International
Union Against Cancer (UICC)
No. of patients Promoter methylation status P value
Methylated Unmethylated
Age (years) NS
<60 37 30 7
≥60 13 10 3
Sex NS
Male 35 28 7
Female 15 11 4
Cancer stagea NS
I 4 3 1
II 15 12 3
III 17 12 5
IV 14 12 2
Histological subtype NS
Keratinizing squamous cell carcinoma 7 6 1
Non-keratinizing carcinoma 43 35 8
Lymph node metastasis P<0.05
Presence 33 33 0
Absence 17 10 7
Fig. 3 Ectopic expression of
CYB5R2 inhibits colony
formation, migration and
proliferation of NPC cells. a
Colony formation ability of
CYB5R2-transfected and empty
vector-transfected HONE1cells.
Colony numbers in the bar graph




HONE1cells examined by wound
healing assay. c Growth curves of
CYB5R2-transfected, empty
vector-transfected HONE1cells
and parental cells. Data are mean
±SD (n =5). *P<0.05
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contribute to the carcinogenic development in NPC [21].
Occupational exposure to formaldehyde and wood dust are
risk factors as well [22–24]. Moreover, cigarette smoke has
been consistently found as a moderate risk factor for NPC [7,
25]. Polycyclic aromatic hydrocarbons, nitrosamines and ar-
omatic amines are known carcinogens in cigarette smoke [26,
27]. These aromatic amines can either be activated to carci-
nogenic aromatic hydroxylamine derivatives in the cyto-
chrome P450 pathway or detoxified by N -acetylation in the
cytochrome B5 reductase (CYB5R) pathway [16]. The
nitrenium or nitroso derivatives produced in the cytochrome
P450 activation pathway generate mutagenic DNA adducts
while the end products of the CYB5R mediated detoxification
pathway are cleared as N-acetylated, water soluble products.
Alterations of genes that encode phase I and phase II xenobi-
otic biotransformation enzymes [9], involved in metabolic
activation or detoxification of potentially carcinogenic sub-
stances, have been demonstrated as risk factors for NPC
[10–13].
In the present study, we demonstrate that the mRNA ex-
pression of a xenobiotic-metabolizing enzyme, CYB5R2 , was
downregulated in NPC cell lines and primary tumors. The
CYB5R2 promoter was aberrantly methylated in all six NPC
cell lines (100%) and in 42 of 50 (84%) primary NPC tumors,
but not in any of the 12 normal controls. Bisulphite genomic
sequencing demonstrated that all 39 CpG sites in the tested
CYB5R2 promoter were heavily methylated in the NPC cell
lines CNE2 and TW03, where CYB5R2 expression is down-
regulated. A high degree of methylation was also observed in
primary NPC tumors. CYB5R2 expression could be restored
in four NPC cell lines after treatment with the demethylating
agent 5-aza-dC. These results indicate that CYB5R2 was
transcriptional inactivation in NPC, and the major mechanism
could be a high degree of methylation in its promoter region,
which might contribute to the tumorigenesis of NPC.
The expression of CYB5R2 has been evaluated in several
human malignancies. Consistent with our findings, microar-
ray analysis revealed that CYB5R2 is downregulated in lobu-
lar and ductal invasive breast cancer biopsies and functions as
a regulator of cell proliferation, differentiation and transfor-
mation [28]. However, these findings are inconsistent with
observations in acute B lymphoblastic leukemia, in which
CYB5R2 is upregulated [29]. Thus, epigenetic inactivation
of CYB5R2 might be tissue-specific events.
Hypermethylated DNA can serve as a biomarker for cancer
detection because of its high specificity in distinguishing
cancers from normal tissues. We found that the CYB5R2
promoter region was subject to methylation in all of our six
NPC cell lines and 84% ofNPC biopsies. Therefore,CYB5R2
promoter hypermethylation is a frequent event in NPC and not
just a phenomenon associated with in vitro cell culture. In
addition, epigenetic silencing of CYB5R2 was a tumor-
specific event and could be detected in both early- and
advanced-stage NPC biopsies, which suggests that CYB5R2
promoter hypermethylation might contribute both to the initi-
ation and progression of NPC. CYB5R2 methylation could
serve as a potential biomarker for early diagnosis of NPC.
However, due to the lack of patients' follow-up study, we
suffered from the limitation that no correlation between the
expression of CYB5R2 and the survival rate of NPC patients
was verified.
Lymph node metastasis is one of the most significant
features of NPC [30]. It is strongly correlated to reduced
survival rate and increased risk of tumor recurrence. Identifi-
cation of biomarkers for lymph nodemetastasis in NPCwould
be helpful in designing optimized and individualized thera-
peutic regimens for NPC. Our finding that CYB5R2 promoter
Fig. 4 CYB5R2 reexpression reduces tumorigenicity of NPC cells in
nudemice. a Growth curves of tumors in nudemice. Themean volume of
tumors from CYB5R2-HONE1 and empty vector-HONE1 cells was
evaluated every 2 days after inoculation. Data are mean±SD (n =8). b
Representative tumors were removed from the nude mice at day 14 after
transplantation. c Mean ± SD weight of tumors (n =8). *P <0.05
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methylation is associated with lymph node metastasis in NPC,
suggests that CYB5R2 promoter methylation may serve as a
diagnostic indicator of lymph node metastasis, which would
have great value for the clinical evaluation of NPC cases.
We show that ectopic expression of CYB5R2 significantly
inhibited cell proliferation, colony formation and migration of
NPC cells in vitro. Moreover, exogenous expression of
CYB5R2 inhibits tumorigenicity of NPC cells in vivo in a
mouse model system. This evidence strongly implies that
CYB5R2 is a putative TSG and plays a role in nasopharyngeal
carcinogenesis. To our knowledge, this is the first report of a
xenobiotic-metabolizing enzyme functioning as a tumor sup-
pressor in NPC.
In summary, our data demonstrate for the first time that
CYB5R2 is epigenetically inactivated by promoter hyperme-
thylation in a human cancer, NPC. Our experimental data
provide support for CYB5R2 as a novel and important candi-
date TSG in NPC. We revealed a frequent and tumor-specific
hypermethylation of the CYB5R2 promoter in NPC and a
significant association of CYB5R2 promoter hypermethyla-
tion with lymph node metastasis, which suggests that the
epigenetic state of the CYB5R2 promoter may serve as a
diagnostic biomarker and present a possible therapeutic target
for NPC.
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